Scholarlink

<p>Cuproptosis is a type of programmed cell death that has been shown to significantly improve cancer radiosensitivity. The tumor microenvironment, characterized by glycolytic activity, suppresses cuproptosis, with the increase of pyruvate kinase M2 (PKM2) lactylation serving as the principal regulators of the switch to glycolysis in hypoxic tumor settings. To address this issue, we proposed a hypoxia-alleviation-driven strategy using a glucose-driven engineered glucose oxidase (GOx)/Cu-based nanozyme composite aimed at activating the PKM2 lactylation “switch” to enhance cuproptosis for improved cancer radiotherapy. This is accomplished through a dual-enzyme cuproptosis inducer featuring a self-supplying H<sub>2</sub>O<sub>2</sub> catalytic system, which co-encapsulates GOx and catalase-like copper sulfide nanoparticles (CuS NPs) within AS1411 aptamer-modified liposomes. GOx utilizes intratumoral glucose to generate H<sub>2</sub>O<sub>2</sub>, which is then converted into O<sub>2</sub> by CuS NPs, alleviating tumor hypoxia. The oxygenated microenvironment inhibits HIF-1α and PKM2 lactylation, altering metabolism from glycolysis to mitochondrial respiration. Flipping this metabolic “switch” amplifies Cu<sup>2+</sup>-mediated cuproptosis and increases cancer radiosensitivity, ultimately offering a novel approach for the clinical treatment of radioresistant cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A glucose-driven engineered glucose oxidase/Cu-based nanozyme composite for flipping the PKM2 lactylation “switch” toward amplified cuproptosis and enhanced cancer radiosensitivity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月1日

查看全文
  • Dehong Chen,
  • Peng Chang,
  • Kuoye Tian,
  • Xiaoyu Yang,
  • Tianhang Wang,
  • Liwen Cui,
  • Shuai Zhao,
  • Ke Li,
  • Dan Chen,
  • Haiyang Lu,
  • Xu Cao,
  • Yun Zeng,
  • Yonghua Zhan,
  • Wenhua Zhan

摘要

Cuproptosis is a type of programmed cell death that has been shown to significantly improve cancer radiosensitivity. The tumor microenvironment, characterized by glycolytic activity, suppresses cuproptosis, with the increase of pyruvate kinase M2 (PKM2) lactylation serving as the principal regulators of the switch to glycolysis in hypoxic tumor settings. To address this issue, we proposed a hypoxia-alleviation-driven strategy using a glucose-driven engineered glucose oxidase (GOx)/Cu-based nanozyme composite aimed at activating the PKM2 lactylation “switch” to enhance cuproptosis for improved cancer radiotherapy. This is accomplished through a dual-enzyme cuproptosis inducer featuring a self-supplying H2O2 catalytic system, which co-encapsulates GOx and catalase-like copper sulfide nanoparticles (CuS NPs) within AS1411 aptamer-modified liposomes. GOx utilizes intratumoral glucose to generate H2O2, which is then converted into O2 by CuS NPs, alleviating tumor hypoxia. The oxygenated microenvironment inhibits HIF-1α and PKM2 lactylation, altering metabolism from glycolysis to mitochondrial respiration. Flipping this metabolic “switch” amplifies Cu2+-mediated cuproptosis and increases cancer radiosensitivity, ultimately offering a novel approach for the clinical treatment of radioresistant cancers.